The Claim

In adults with type 2 diabetes, once-weekly exenatide does not significantly reduce the risk of developing macroalbuminuria, with a hazard ratio of 0.87 (95% confidence interval: 0.70–1.07), indicating no statistically significant protective effect on this marker of kidney damage.

Source: Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
82score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Quantitative
1 study reviewed
In plain English

Taking a weekly diabetes shot called exenatide doesn’t seem to lower the risk of a specific type of kidney problem in adults with type 2 diabetes — the numbers don’t show a clear benefit.

See the scientific wording

Once-weekly exenatide does not significantly reduce the risk of incident macroalbuminuria in adults with type 2 diabetes, with a hazard ratio of 0.87 (95% CI 0.70–1.07), indicating no statistically significant protective effect on this marker of kidney damage.

What the research says

1 study

  1. Study: Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial

    The study looked at whether a diabetes drug called once-weekly exenatide helps prevent kidney damage, and found it didn’t make a big enough difference to be considered effective. That matches what the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.